IDH1 and glioma: Concentrations of 2-hydroxyglutarate enantiomers, currently a recognized gliomas biomarker, are elevated by orders of magnitude in gliomas harboring mutations in isocitrate dehydrogenase1/2 (IDH1/2) [34].